JAGX

Jaguar Animal Health Inc

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.

Jaguar Animal Health Inc (JAGX) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.6
Rev Growth YoY N/M
Gross Margin 85.1%
Price Return 3M -69.2%
Price Return 12M -98.6%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.2
ROE -411.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.3) B (3.3) C (2.4) C- (1.9) C+ (2.5)
2026-08-04 C+ (2.7) C (2.3) B (3.3) C (2.4) C- (1.9) C+ (2.5)
2026-08-03 C+ (2.7) C (2.4) B (3.2) C (2.4) C- (2.0) C+ (2.5)
2026-08-02 C+ (2.7) C (2.4) B- (3.1) C (2.4) C- (1.9) C+ (2.5)
2026-07-29 C+ (2.6) B+ (3.6) C+ (2.6) F (0.2) D+ (1.5) C- (2.1)
Page 1 of 2